Valink Therapeutics: Valuation, Funding & Investors
Valink Therapeutics Inc. is a biotechnology company developing first-in-class bispecific antibody-drug conjugates (bsADCs) and other modalities for improved patient outcomes. Valink’s proprietary discovery platform and V-gate™ approach address key challenges of current technologies by expanding the toolbox of available approaches for bispecific antibody therapeutics and bispecific ADCs, unlocking fine-tuned target control, functional outcomes, and improved therapeutic index.
Leadership & Board
- Current Number of Employees
- 30
- Current LinkedIn Followers
- 3,883
Latest Estimated Valuation
- Total Amount Raised
- $12M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $12M
- Latest Funding Round
- Series A
Employee Trend
Valink Therapeutics had 30 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Valink Therapeutics had 3,883 followers as of November 9, 2026. The number of followers increased by 5 (0.13%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 20, 2025 | Series A | $11.80M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Oxford Science Enterprises | Series A |
| RV Invest | Series A |
| redalpine | Series A |
| Hoxton Ventures | Series A |
| LongeVC | Series A |
| p53 Invest | Series A |
Similar Companies
A snapshot of private companies similar to Valink Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis








